Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Pituitary Gland Carcinoma

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

CNS Tumor (591)

Brain Cancer (583)

Neuroblastoma (59)

CNS Tumor (591)

Brain Cancer (583)

Neuroblastoma (59)

›

MGMT underexpression	Pituitary Gland Carcinoma	MGMT underexpression	Pituitary Gland Carcinoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
TMB-L + PD-L1 underexpression	Pituitary Gland Carcinoma	TMB-L + PD-L1 underexpression	Pituitary Gland Carcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
SDHB mutation	Pituitary Gland Carcinoma	SDHB mutation	Pituitary Gland Carcinoma	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4
MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
STK11 mutation	Pituitary Gland Carcinoma	STK11 mutation	Pituitary Gland Carcinoma	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4
STK11 mutation	Pituitary Gland Carcinoma	STK11 mutation	Pituitary Gland Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
ATRX mutation + TP53 mutation + PTEN mutation	Pituitary Gland Carcinoma	ATRX mutation + TP53 mutation + PTEN mutation	Pituitary Gland Carcinoma	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4
TMB-H	Pituitary Gland Carcinoma	TMB-H	Pituitary Gland Carcinoma	nivolumab + ipilimumab Resistant: C4 – Case Studies nivolumab + ipilimumab Resistant : C4	nivolumab + ipilimumab Resistant: C4 – Case Studies nivolumab + ipilimumab Resistant : C4
TMB-H	Pituitary Gland Carcinoma	TMB-H	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4
MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4